160 related articles for article (PubMed ID: 15039804)
1. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
[TBL] [Abstract][Full Text] [Related]
2. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
3. Current treatment options in prolymphocytic leukemia.
Robak T; Robak P
Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
[TBL] [Abstract][Full Text] [Related]
5. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in peripheral T-cell malignancies.
Dearden C
Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
[TBL] [Abstract][Full Text] [Related]
7. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
8. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
[TBL] [Abstract][Full Text] [Related]
9. Mature T-cell leukemias.
Ravandi F; Kantarjian H; Jones D; Dearden C; Keating M; O'Brien S
Cancer; 2005 Nov; 104(9):1808-18. PubMed ID: 16136598
[TBL] [Abstract][Full Text] [Related]
10. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
Chaar BT; Petruska PJ
Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
[No Abstract] [Full Text] [Related]
11. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
12. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
14. T-cell prolymphocytic leukemia.
Dearden CE
Med Oncol; 2006; 23(1):17-22. PubMed ID: 16645226
[TBL] [Abstract][Full Text] [Related]
15. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
[TBL] [Abstract][Full Text] [Related]
16. T-cell prolymphocytic leukemia.
Khot A; Dearden C
Expert Rev Anticancer Ther; 2009 Mar; 9(3):365-71. PubMed ID: 19275513
[TBL] [Abstract][Full Text] [Related]
17. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
Vivekanandarajah A; Atallah JP; Gupta S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
[TBL] [Abstract][Full Text] [Related]
18. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
19. Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris JC; Waldmann TA; Janik JE
J Immunotoxicol; 2008 Apr; 5(2):235-48. PubMed ID: 18569395
[TBL] [Abstract][Full Text] [Related]
20. T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]